Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CMNDBullishIndustry Newsnews

High materiality8/10

Clearmind CMND-100 shows positive early signals in AUD trial

Jul 13, 2026, 8:19 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive early trial signals, non-hallucinogenic MEAI profile, and strong academic collaborations may attract buyers and expand the addressable AUD-treatment narrative; mitigated by early-stage risk.

AI summary

What happened, with direct paths to the underlying reporting

Clearmind Medicine reports positive early impressions from June 10 on CMND-100 in its Phase I/IIa trial for alcohol use disorder. Yale and Johns Hopkins investigators cite unmet AUD needs, non-hallucinogenic MEAI advantages, and a favorable safety profile. Potential broader applications are noted, with recruitment advancing smoothly.

CMND-100 Phase I/IIa shows positive early safety signals.
Non-hallucinogenic MEAI differentiates from psychedelics.
Recruitment progressing well despite strict healthy-volunteer criteria.
Early safety profile: no meaningful adverse or cardiac concerns observed.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Clearmind CMND-100 shows positive early signals in AUD trial

DSMB approves CMND-100 advancement to AUD patient cohorts, signaling clinical progress

Clearmind Medicine Achieves Key Milestone for Alcohol Use Disorder Treatment